Starpharma Holdings Ltd - ESG Rating & Company Profile powered by AI
This page contains a Q&A table on Starpharma Holdings Ltd. This Disclosure rating covers 17 United Nations SDGs including: 'Affordable & Clean Energy', 'Climate Action' and 'Peace, Justice & Strong Institutions'. Browse to the bottom of the page for potential risks for Starpharma Holdings Ltd based on industry, location and marketcap.
Starpharma Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 4.0, social score of 8.0 and governance score of 8.0.
6.7
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
314 | Trulieve Cannabis Corp | 6.8 | High |
314 | Vicore Pharma Holding AB | 6.8 | High |
337 | Starpharma Holdings Ltd | 6.7 | High |
337 | Calyxt Inc | 6.7 | High |
337 | CanSino Biologics Inc | 6.7 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Starpharma Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Starpharma Holdings Ltd disclose current and historical energy intensity?
Does Starpharma Holdings Ltd report the average age of the workforce?
Does Starpharma Holdings Ltd reference operational or capital allocation in relation to climate change?
Does Starpharma Holdings Ltd disclose its ethnicity pay gap?
Does Starpharma Holdings Ltd disclose cybersecurity risks?
Does Starpharma Holdings Ltd offer flexible work?
Does Starpharma Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Starpharma Holdings Ltd disclose the number of employees in R&D functions?
Does Starpharma Holdings Ltd conduct supply chain audits?
Does Starpharma Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Starpharma Holdings Ltd conduct 360 degree staff reviews?
Does Starpharma Holdings Ltd disclose the individual responsible for D&I?
Does Starpharma Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Starpharma Holdings Ltd disclose current and / or historical scope 2 emissions?
Does Starpharma Holdings Ltd disclose water use targets?
Does Starpharma Holdings Ltd have careers partnerships with academic institutions?
Did Starpharma Holdings Ltd have a product recall in the last two years?
Does Starpharma Holdings Ltd disclose incidents of discrimination?
Does Starpharma Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has Starpharma Holdings Ltd issued a profit warning in the past 24 months?
Does Starpharma Holdings Ltd disclose parental leave metrics?
Does Starpharma Holdings Ltd disclose climate scenario or pathway analysis?
Does Starpharma Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Starpharma Holdings Ltd disclose the pay ratio of women to men?
Does Starpharma Holdings Ltd support suppliers with sustainability related research and development?
Does Starpharma Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Starpharma Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Starpharma Holdings Ltd involved in embryonic stem cell research?
Does Starpharma Holdings Ltd disclose GHG and Air Emissions intensity?
Does Starpharma Holdings Ltd disclose its waste policy?
Does Starpharma Holdings Ltd report according to TCFD requirements?
Does Starpharma Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Starpharma Holdings Ltd disclose energy use targets?
Does Starpharma Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Starpharma Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Starpharma Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.